Complete Genomics and SOPHiA GENETICS Announce Integration of MSK-IMPACT® and MSK-ACCESS® Assays on DNBSEQ-T1+ Platform at AMP 2025

Rhea-AI Summary

Complete Genomics and SOPHiA GENETICS (NASDAQ: SOPH) announced integration of MSK-IMPACT® and MSK-ACCESS® powered by SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform, unveiled at AMP 2025 on November 11, 2025. The collaboration offers a sample-to-report workflow for decentralized labs to scale precision oncology testing.

The DNBSEQ-T1+ delivers Q40-level accuracy, 500 million–2 billion reads per flow cell, a 24-hour paired-end 150bp run time, and can process up to 60 tumor-normal tissue pairs or 16 tumor-normal liquid biopsy pairs per flow cell at max throughput. Joint evaluation reported highly concordant variant calls, lower background noise, and reduced turnaround time versus equivalent systems.

Positive

• Q40-level accuracy on DNBSEQ-T1+
• 500M–2B reads per flow cell throughput
• Up to 60 tissue tumor-normal pairs per flow cell
• Up to 16 liquid biopsy tumor-normal pairs per flow cell
• Concordant variant calls with equivalent systems
• Lower background noise and reduced turnaround time

Negative

• None.

Insights

Precision oncology partnerships analyst

Integration of MSK-IMPACT® and MSK-ACCESS® on the DNBSEQ-T1+ expands scalable, high‑accuracy genomic profiling for decentralized labs.

The collaboration pairs SOPHiA GENETICS analytics and MSK‑validated assays with Complete Genomics' DNBSEQ-T1+ sequencer to deliver an end-to-report workflow for laboratories. The platform claims Q40-level accuracy, throughput from 500 million to 2 billion reads per flow cell, a 24-hour paired-end run time, and capacity up to 60 tumor-normal tissue pairs or 16 liquid biopsy pairs per flow cell, enabling higher sample density and operational flexibility.

Reported joint evaluation showed highly concordant variant calls and allele frequencies versus equivalent systems, plus lower background noise and reduced turnaround time; those technical claims support lab adoption if independently reproduced. Main dependencies include local validation, regulatory/lab accreditation alignment, and real-world performance at scale; adoption will hinge on confirmed cost-per-sample economics and integration into existing SOPHiA DDM™ workflows.

Watch for independent lab validation data, comparative workflow cost metrics, and post-deployment performance over the next 6–18 months, and for any regulatory or reimbursement disclosures that affect clinical use; the announcement was presented at AMP 2025 (booths listed Nov 11–15, 2025), which may yield follow-up data releases.

BOSTON, Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally. The announcement was made from the Association for Molecular Pathology (AMP) 2025 Annual Meeting in Boston.

The collaboration integrates SOPHiA GENETICS' advanced, AI-powered applications MSK-IMPACT® and MSK-ACCESS® powered by SOPHiA DDM™, developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), with Complete Genomics' newly launched DNBSEQ-T1+ sequencing platform. Together, Complete Genomics and SOPHiA GENETICS will provide an integrated, sample-to-report workflow for laboratories, marking a significant expansion of their partnership into the precision oncology market.

"Pairing MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM™ with our DNBSEQ-T1+ platform creates a powerful and accessible solution for laboratories looking to scale high-quality cancer genomic profiling," said Rob Tarbox, vice president of product and marketing at Complete Genomics. "By combining MSK's rigorously validated assays, SOPHiA GENETICS' robust analytics, and our sequencing technology, we are enabling decentralized labs to deliver faster, more accurate, and more affordable insights to clinicians and researchers."

"This collaboration underscores SOPHiA GENETICS' commitment to broadening access to data-driven medicine," said Ross Muken, President, SOPHiA GENETICS. "Partnering with Complete Genomics to streamline use of MSK-IMPACT® and MSK-ACCESS® powered with SOPHiA DDM™ on the DNBSEQ-T1+ platform enables more laboratories around the world to adopt precision oncology through scalable, end-to-end genomic solutions."

The DNBSEQ-T1+, powered by proprietary DNBSEQ technology, delivers Q40-level accuracy, optimized throughput from 500 million to 2 billion reads per flow cell. Each flow cell is able to be run independently, with a 24-hour paired-end 150bp run time, offering laboratories a cost-effective and highly flexible sequencing solution. At maximum throughput, each T1+ flow cell can run up to 60 tumor-normal sample pairs for tissue, or up to 16 tumor-normal sample pairs for liquid biopsy.

SOPHiA DDM™ is a technology-agnostic analytics platform that leverages AI to compute, standardize, and analyze healthcare data. Joint evaluation of MSK-IMPACT® and MSK-ACCESS® on the DNBSEQ-T1+ platform demonstrated highly concordant variant calls and allele frequencies compared with equivalent sequencing systems, while achieving lower background noise, reduced turnaround time, and seamless compatibility with existing SOPHiA DDM™ workflows. 

This new offering provides clinical laboratories, cancer centers, and drug developers with a high-performance, cost-efficient path to implementing comprehensive genomic profiling for precision oncology research.

To learn more, visit the Complete Genomics Booth 1210 or SOPHiA GENETICS Booth 921 at AMP from November 11–15, 2025 or visit www.CompleteGenomics.com and  www.SOPHiAGENETICS.com.

About Complete Genomics
Complete Genomics is a pioneering life sciences company that provides novel, complete sequencing solutions including sample/library preparation, lab automation, sequencing, and data analysis. The sequencing portfolio offers a full lineup of sequencers ranging from low, medium, and high throughput capacities, all powered by its proprietary DNBSEQ technology. More than 10,900 publications are based on DNBSEQ technology across a wide array of applications. To learn more, visit www.completegenomics.com.

* For Research Use Only. Not for use in diagnostic procedures.

About SOPHiA GENETICS  
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. 

SOPHiA DDM™ is for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com  to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements: 
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 

View original content:https://www.prnewswire.com/news-releases/complete-genomics-and-sophia-genetics-announce-integration-of-msk-impact-and-msk-access-assays-on-dnbseq-t1-platform-at-amp-2025-302610509.html

SOURCE Complete Genomics

FAQ

What did SOPH and Complete Genomics announce at AMP 2025 on November 11, 2025?

They announced integration of MSK-IMPACT® and MSK-ACCESS® on the DNBSEQ-T1+ platform to deliver a sample-to-report precision oncology workflow.

How many tumor-normal sample pairs can a DNBSEQ-T1+ flow cell run for tissue and liquid biopsy?

At maximum throughput a T1+ flow cell can run up to 60 tumor-normal tissue pairs or up to 16 tumor-normal liquid biopsy pairs.

What accuracy and run time does the DNBSEQ-T1+ offer for SOPH analytics?

The DNBSEQ-T1+ delivers Q40-level accuracy with a 24-hour paired-end 150bp run time per flow cell.

Will MSK-IMPACT® and MSK-ACCESS® on DNBSEQ-T1+ match existing sequencing systems?

Joint evaluation showed highly concordant variant calls and allele frequencies compared with equivalent sequencing systems.

How does the integrated offering affect laboratory turnaround time and noise?

The joint solution demonstrated reduced turnaround time and lower background noise versus equivalent systems.

Where can investors or labs learn more about the SOPH and Complete Genomics collaboration during AMP 2025?

Visit Complete Genomics Booth 1210 or SOPHiA GENETICS Booth 921 at AMP Nov 11–15, 2025, or the companies' websites.